Citations

Showing 10 of 108083 citations.

High GILT expression and an active and intact MHC class II antigen presentation pathway are associated with improved survival in melanoma
Meador, Lydia R., Lu, Yih-Kaung, Brill, Jacob, Cui, Haiyan, Roe, Denise J. , DiCaudo, David J. , Buetow, Kenneth H. , Hastings, Karen Taraszka , Menon, Hari

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 177.32-177.32

10.4049/jimmunol.202.supp.177.32 Get It

Abstract The MHC class I antigen presentation pathway in melanoma cells has a well-established role in immune-mediated destruction of tumors. However, the clinical significance of the MHC class II antigen presentation pathway in melanoma cells is less clear. In antigen presenting cells, gamma-interferon-inducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens. While not expressed in benign melanocytes of nevi, GILT and MHC class II expression is induced in malignant melanocytes in a portion of melanoma specimens. Analysis of The Cancer Genome Atlas (TCGA) cutaneous melanoma dataset showed that high GILT mRNA expression was associated with improved overall survival. Expression of IFN-γ, TNF-α, and IL-1β was positively associated with GILT expression in the TCGA melanoma specimens. These cytokines were capable of inducing GILT expression in melanoma cells in vitro. GILT protein expression in melanocytes was induced in halo nevi, which are nevi undergoing immune-mediated regression, and is consistent with the association of GILT expression with improved survival in melanoma. To explore potential mechanisms of GILT’s association with patient outcome, we analyzed the mRNA expression pattern in the MHC class II antigen presentation pathway. In contrast to healthy skin where the MHC class II pathway was nearly uniformly expressed and intact, there was substantial variation in the MHC class II pathway of the TCGA melanoma dataset. Both an active and intact MHC class II pathway were associated with improved overall survival in melanoma. These studies support a role for GILT and the MHC class II antigen presentation pathway in melanoma outcome.
An engineered vaccine encompassing an MHC class I antigen presenting molecule induces self-reacting CTL in a setting of profound tolerance
Pease, Larry R. , Parks, Christopher A. , Kranz, David M. , Barry, Michael J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 177.30-177.30

10.4049/jimmunol.202.supp.177.30 Get It

Abstract Engineered antigen presenting molecules can promote allorecognition and activate CTL capable of recognizing weak or self-antigens in the context of self-MHC. Traditionally, allogeneic antigen presenting molecules differ from self MHC molecules in their interactions with the bound peptides and with TCR expressed in the immune repertoire to promote peptide dependent alloimmunity. Alloreactive T cells target their inducing alloantigens, as well as third-party alloantigens, but as a result of tolerance, generally not self-antigen presenting molecules. Certain residues located on the alpha-1/2 domains of class I antigen presenting molecules interface with TCR CDR loops and do not influence the nature or orientation of bound peptides. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures at this MHC:TCR interface are found to provide strong activating signals to alloreactive CD8 T cells in the self tolerant immune repertoire. We demonstrate that CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents a novel approach for inducing autoimmunity, with possible application the development of cancer vaccines.
Activation of microglia in CD8 T cell-initiated blood-brain barrier disruption induced during Theiler’s virus infection
Khadka, Roman H., Trtiz, Zachariah, Johnson, Aaron J. , Zheng, Jiaying , Ayasoufi, Katayoun , Jin, Fang , Wu, Long‐Jun , Johnson, Aaron

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 76.2-76.2

10.4049/jimmunol.202.supp.76.2 Get It

Abstract Immune-mediated blood brain barrier (BBB) disruption is a prominent feature of various neurological conditions for which an emerging role of CD8 T cells is being realized. Our laboratory has developed a model of CD8 T cell-mediated BBB disruption which employs a variation of the Theiler’s murine encephalomyelitis virus (TMEV) infection. At seven days post TMEV infection, the majority of antiviral CD8 T cells recognize an immunodominant virus peptide, VP2121–130, in the context of the H-2Db class I molecule. Upon intravenous administration of this VP2 peptide at seven days post infection, Db:VP2121–130 epitope specific CD8 T cells induce BBB in a perforin dependent process. In this model, we addressed the role of microglia in tandem with CD8+ T cells. Using real time two-photon in vivo imaging, we demonstrate that microglia adopt distinct morphological features including enlarged cell body and fewer ramified processes as early as 6 hours post administration of VP2 peptide. Notably, perforin-deficient mice failed to display BBB disruption and had significantly diminished microglial expression of MHC-II and CD68 in this model. This study demonstrates CD8 T cell promote microglia activation through a perforin-dependent process during BBB disruption. Importantly, microglia are activated concurrently with the onset of vascular permeability and could serve as a critical cell type in this process.
CD8 T cells initiate blood-brain barrier disruption during experimental cerebral malaria through non-cytotoxic alterations to endothelial cells
Johnson, Aaron J. , Jin, Fang , Johnson, Aaron J

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 198 | Issue: Supplement_1 | Pages: 123.12-123.12

10.4049/jimmunol.198.supp.123.12 Get It

Abstract Cerebral malaria is a serious health complication that can arise during Plasmodium infections. Symptoms of human cerebral malaria (HCM) include coma, permanent neurological deficits, and potentially death. While the mechanism is not well understood, brain swelling and edema have been shown to correlate with a poor disease outcome for afflicted individuals. This work attempts to identify the cellular changes occurring during breakdown of the blood-brain barrier (BBB) by utilizing the murine model of experimental cerebral malaria (ECM). Previous work determined that the tight junctions claudin-5 and occludin, proteins essential for regulating BBB integrity, were disorganized on cerebral endothelial cells during ECM. Here, we focus on the constituents of the BBB to characterize the changes occuring within endothelial cells during disease progression. Importantly, endothelial cell changes were not strictly induced by parasitic infection itself, but also required the presence of functional CD8 T cells. Using perforin deficient mice to impair CD8 T cell effector function, we demonstrate that brain endothelial cells retain the characteristics of uninfected animals in contrast to wild-type infected mice. Interestingly, the CD8 T cells appear to be acting independently of direct killing as there is not an increase in activation of the apoptotic pathway nor is there an increase in dead or dying endothelial cells. From these data we propose that non-cytotoxic CD8 T cell functions are required for ECM induction.
Molecular mechanisms regulating CXCR4 mediated cytokine mRNA stability
Dinkel, Brittney A., Kremer, Kimberly N. , Hedin, Karen E.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 198 | Issue: Supplement_1 | Pages: 52.26-52.26

10.4049/jimmunol.198.supp.52.26 Get It

Abstract T cell cytokine production has been shown to be dependent not only on T cell antigen receptor (TCR), but also the chemokine receptor CXCR4. Evidence in the literature suggests that, in addition to stimulating migration, CXCR4 might also more directly regulate T cell immune activation. Recent studies from our lab have revealed that TCR stimulation in the absence of SDF-1 induces association of TCR and CXCR4, and that this is inhibited by pretreating cells with the specific CXCR4 antagonist AMD3100. Cytokine production, particularly cytokines IL-2, IL-4, and IL-10, by TCR-stimulated cells was inhibited by using either AMD3100 or CXCR4 siRNA to prevent TCR-CXCR4 formation. Interestingly, TCR-CXCR4 was not required for activation of many TCR-stimulated signaling pathways or for cytokine gene transcription. Instead, TCR-CXCR4 formation during TCR-mediated T cell immune activation was required for the post-transcriptional stabilization of cytokine mRNAs through a Rac-1 mediated pathway. Our results suggest that targeting the TCR-CXCR4 complex formation or downstream signaling pathways may provide therapeutic targets to regulate cytokine production.
MHC class I expression by microglia is required for generating a complete antigen-specific CD8 T cell response in the CNS
Malo, Courtney S. , Fryer, John Denis , Johnson, Aaron J. , Jin, Fang , Hansen, Michael J, Pavelko, Kevin D. , Johnson, Aaron J

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 99.7-99.7

10.4049/jimmunol.200.supp.99.7 Get It

Abstract Microglia are central nervous system (CNS) resident immune cells for which the impact of MHC class I antigen presentation is still being defined. To directly address if microglia contribute to CD8 T cell-mediated immunity of the CNS, we generated a novel tamoxifen inducible CX3CR1-creER H-2Kb MHC class I conditional knockout mouse. In this transgenic mouse, the H-2Kb MHC class I molecule is deleted on all CX3CR1-expressing cells following tamoxifen treatment. By two weeks post tamoxifen treatment, peripheral CX3CR1-expressing cells repopulate, restoring normal expressing of H-2Kb. This leaves only microglia as the sole MHC class I-deficient cell type. We hypothesized that deletion of H-2Kb on microglia would reduce CD8 T cell responses in the CNS. We challenged these animals and cre-negative littermates with intracranial picornavirus infection with Theiler’s murine encephalomyelitis virus expressing ovalbumin (TMEV-OVA). We also challenged mice with experimental GL261 gliomas. We found that microglia-specific H-2Kb deletion reduces the CD8 T cell response in the CNS and attenuates the activation status of brain-infiltrating CD8 T cells in both models of neuroinflammation. We conclude that microglia are functional antigen presenting cells, and are required for a complete antigen-specific CD8 T cell response in the brain. These findings are the first to definitively address the role of microglia-expressed MHC class I in CNS immunological challenges.
A murine model of suicide gene therapy in the brainstem demonstrates efficacy without toxic inflammation, suggesting possible use as a treatment for diffuse intrinsic pontine glioma (DIPG)
Schuelke, Matt, Thompson, Jill , Rao, Amulya Nageswara, Bram, Richard J. , Vile, Richard G. , Schuelke, Matthew , Evgin, Laura , Daniels, David J. , Rao, Amulya A. Nageswara , Kasahara, Noriyuki

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 198 | Issue: Supplement_1 | Pages: 198.15-198.15

10.4049/jimmunol.198.supp.198.15 Get It

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare pediatric brainstem tumor that is the leading cause of death among pediatric brain malignancies. Despite over 200 clinical trials, no significant progress has been made, leading our lab to consider suicide gene therapy. The brainstem has particularly sensitive anatomy, creating the potential for toxic inflammation. Furthermore, the clinical standard of care for DIPG includes conventional radiation therapy (RT) followed by dexamethasone (DEX), each of which can alter the efficacy of gene therapy. In this study we found that a variety of gliomas, including human DIPG and murine glioma cell lines, are infectable in vitro with a replication-competent Moloney murine leukemia virus (MoMLV) (currently in Phase 2/3 clinical trials) and susceptible to ganciclovir (GCV)-mediated killing via the HSV thymidine kinase (tk) suicide gene. A B16 melanoma cell line expressing HSV tk implanted into the brainstem of mice, extended median survival with GCV therapy from 13 days to 38.5 days (p=.0006) with no signs of toxic inflammation. Pre-treatment with RT and DEX did not affect therapeutic efficacy. We have shown that GCV/TK therapy is mediated by NK and CD8 cells in subcutaneous tumors, and we are investigating whether a similar immunologic mechanism is involved in this brainstem model. These preclinical data will pave the way for novel clinical trials for the treatment of DIPG.
Therapeutic effect of Lactobacillus reuteri DSM 17938 on Treg-deficiency-induced autoimmunity (IPEX syndrome) via the inosine-adenosine 2A receptors
He, Baokun , Hoang, Thomas K. , Wang, Ting , Tian, Xiangjun , Luo, Meng , Tran, Dat Q. , Zhou, Jain, Tatevian, Nina , Luo, Fayong , Molina, Jose G., Gomez, Thomas H., Liu, Yuying , Taylor, Christopher M. , Blackburn, Michael R. , Roos, Stefan , Rhoads, J. Marc

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 198 | Issue: Supplement_1 | Pages: 127.22-127.22

10.4049/jimmunol.198.supp.127.22 Get It

Abstract Regulatory T-cell (Treg) deficiency causes lethal, CD4+T cell-driven autoimmune diseases. Stem cell transplantation is used to treat these diseases, but this procedure is limited by the availability of a suitable donor. The intestinal microbiota drives host immune homeostasis by regulating the development of Treg, Th1 and Th2 cells. It is currently unclear if Treg-deficiency autoimmune disorders can be treated by targeting the enteric microbiota. Our aims are to determine the autoimmunity, gut microbiota, and plasma metabolomics affected by probiotic Lactobacillus reuteri DSM 17938 (LR), and to further identify the mechanism of modulated metabolite(s) in suppressing autoimmunity in Treg-deficient scurfy (SF) mice. We demonstrated that Foxp3+Treg deficiency results in gut microbial dysbiosis and autoimmunity over the lifespan of SF mouse. Remodeling microbiota with LR prolonged survival and reduced multi-organ inflammation in SF mice. LR changed the metabolomics profile disrupted by Treg-deficiency with a major effect of restoring levels of the purine metabolite inosine. Feeding inosine itself prolonged life and inhibited multi-organ inflammation by reducing Th1/Th2 cells and their associated cytokines. Mechanistically, the inhibition of inosine on the differentiation of Th1 and Th2 cells in vitro depended on adenosine A2A receptors. Both A2A receptor specific antagonist or genetically knockout A2A to SF mice reversed the anti-inflammatory effects of both inosine and LR in vivo. In conclusions, A2A receptors mediate a substantial protective effect of inosine and LR. The LR-modulated-microbiota-inosine-A2A axis might represent a potential avenue for combatting autoimmune diseases mediated by Treg dysfunction.
Reevaluating the biochemical valency of native TCR/CD3 complexes isolated from T cells (IRM7P.708)
Reed, Brendan , Pages, Diana Gil, Palmer, Ed, Schrum, Adam G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 61.9-61.9

10.4049/jimmunol.194.supp.61.9 Get It

Abstract The αβ T cell antigen Receptor (TCR) is a multi-protein complex expressed together with CD3 subunits (γδεζ). The conventional model has it as monovalent with a stochiometry of (αβγδε2ζ2); however, some previously published work reported observation of bivalent complexes with two αβ heterodimers. To reevaluate the valency of the TCR, we have subjected T cell digitonin-solubilized complexes to immunoprecipitation detected by flow cytometry (IP-FCM), size exclusion chromatography, and other methods for detecting complex size and subunit composition. Our results indicate that precisely bivalent TCRs are found among surface-expressed complexes independent of cross-linking by strong antigenic ligands. Their detection can be masked in the presence of Coomassie reagent from Blue-native PAGE conditions, or if antibodies used in detection assays are themselves bivalent. Therefore, bivalent TCR/CD3 complexes can be found under the biochemical conditions that have classically defined the minimally expressed TCR/CD3 unit (digitonin solubilization). Further investigation is required to determine the functional relevance of these bivalent TCR complexes, although greater antigenic binding and signaling is predicted over that of monovalent TCRs.
Characterization of human immune phenotypes using a novel transcriptome analysis approach (IRM6P.656)
Keulen, Virginia Van, Felts, Sara J. , Pease, Larry R. , Scheid, Adam D. , Keulen, Virginia P. Van , Zhang, Yuji , Markovic, Svetomir N.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 60.6-60.6

10.4049/jimmunol.194.supp.60.6 Get It

Abstract To test the hypothesis that complex immune phenotypes can be defined by stable gene expression profiles we are using a RNAseq-based transcriptome analysis to relate phenotypes of activated peripheral blood CD4+ cells from healthy subjects and stage IV melanoma patients to their freshly-isolated counterparts. We have defined molecular immune response signatures (MIRS) containing genes that consistently differentiate individuals from one another. Two different phenotypic groups are defined using this approach, both of which are mathematically distinct from randomly-selected groups. First, a MIRS generated using healthy donor T cells stimulated with α-CD3/CD28 beads defines a distinct response phenotype and successfully predicts 17 independent healthy subject and melanoma patient responses, demonstrating the predictive capability of the approach. Second, our comparison of melanoma patient signatures with those of healthy subjects revealed a group of healthy individuals with distinct expression signatures that did not cluster with those of any of the melanoma patients. These results indicate that our RNAseq-based transcriptome analysis has the potential to identify phenotypic groups as well as gene sets that have response-predictive capabilities. Our work has both discovery and translational implications, as our approach can be used to investigate complex genetic contributions to immune responses and predict how individual patients will respond to therapeutic interventions.